Abstract: The present invention relates to the field of therapeutic monoclonal antibodies, and specifically provides an anti-FXI/FXIa antibody or an antigen-binding fragment thereof, nucleic acid molecules encoding same, and methods for preparing same. The anti-FXI/FXIa antibody or antigen-binding fragment thereof described in the present invention has specificity and high affinity to FXI/FXIa, and can effectively inhibit the activity of FXI/FXIa. Therefore, the present invention further provides a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, and a use thereof in the preparation of a drug which is used for the prevention and/or treatment of diseases or disorders related to coagulation or thromboembolism.

Abstract: Provided in the present application are an antibody-drug conjugate, and a preparation method therefor and the use thereof. The antibody drug conjugate has a structure as represented by the formula Ab-[M-L-E-D]x, and the drug is selected from an anti-tubulin agent, a DNA intercalator, a DNA topoisomerase inhibitor and a RNA polymerase inhibitor. The prepared antibody-drug conjugate has a better drug-to-antibody ratio, and has a good targeted killing effect on colon cancer and non-small cell lung cancer (for example, lung adenocarcinoma).

Abstract: The present invention relates to the field of treatment of diseases. Specifically, the present invention relates to an anti-ROR1 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding same, and methods for preparing same. The anti-ROR1 antibody or the antigen-binding fragment thereof of the present invention has high specificity and high affinity for ROR1, and can effectively bind ROR1 and mediate killing of ROR1 expression cells. Therefore, the present invention further relates to a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, and a use thereof in preparation of a drug which is used for prevention and/or treatment of tumors.

Abstract: The present application relates to the field of treatment of diseases, and in particular, to an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-CLDN18.2 antibody or the antigen-binding fragment thereof has high specificity and affinity to CLDN18.2, and can effectively bind to CLDN18.2 and mediate the killing of CLDN18.2 expressing cells. Therefore, the present application further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use thereof in the preparation of drugs, wherein the drugs are used for the prevention and/or treatment of tumors.